Wave Life Sciences Slips as Obesity Data Fails to Convince

Wave Life Sciences (WVE) shares fell nearly 50% to $6.20 after BofA and Wells Fargo cut price targets to $21 and $13 respectively, citing insufficient data for WVE-007 as a standalone obesity treatment and reduced conviction in the liver Activin E knockdown mechanism.

The INLIGHT trial showed 14.3% placebo-adjusted visceral fat reduction with preserved lean muscle, but the Phase 1 cohort included lower-BMI patients than typical obesity studies, leaving monotherapy efficacy unproven in the population most likely to benefit.

Have You read The New Report Shaking Up Retirement Plans? Americans are answering three questions and many are realizing they can retire earlier than expected.

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company’s obesity candidate.

The stock fell nearly 50% on March 26, closing at $6.20 — its lowest level in over a year — as investors concluded the data fell short of what would be needed to establish WVE-007 as a standalone obesity therapy. So far this year, shares of WVE are down more than 60%

BofA lowered its price target to $21 from $38 while maintaining a Buy rating, arguing that more evidence is needed to convince investors of WVE-007’s potential — particularly as a monotherapy. The firm still sees opportunity in higher BMI patients and in combination with incretins or as a post-incretin maintenance treatment.

Have You read The New Report Shaking Up Retirement Plans? Americans are answering three questions and many are realizing they can retire earlier than expected.

Wells Fargo cut its target to $13 from $27, keeping an Overweight rating, but flagged reduced conviction that Activin E knockdown in the liver will reliably drive meaningful fat loss, citing the 400mg cohort data specifically. The firm’s concern centers on whether the mechanism translates into clinically relevant weight reduction at the doses tested so far.

The INLIGHT interim readout reported a 14.3% placebo-adjusted reduction in visceral fat six months after a single dose, alongside preservation of lean muscle mass — a differentiated profile compared to GLP-1 therapies that often reduce muscle alongside fat. Earlier cohort data showed up to 85% mean Activin E reduction at the 400mg dose, yet the market’s reaction suggests target suppression of the biomarker did not translate into the fat-loss magnitude investors were pricing in.